Science Explorer Interactive view Map
Company · Seoul · South Korea

ToolGen (South Korea)

eng.toolgen.comROR OpenAlex
Research works
66
▲ 62% vs 2013–17
Citations
2.8k
42.2 per fractional work
Top-10% rate
21.7%
record average 16.5%
Open access
67%
world 28%

Not ranked overall: ToolGen (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 1.77× its world share, 2 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 10.62× its world share, 10 worksBiochemistry, Geneti…Immunology and Microbiology: 2.79× its world share, 0 worksImmunology and Micro…Neuroscience: 2.23× its world share, 1 worksNeuroscienceEngineering: 0.02× its world share, 0 worksEngineeringMedicine: 1.42× its world share, 5 worksMedicineNursing: 1.27× its world share, 0 worksNursingBusiness, Management and Accounting: 0.12× its world share, 0 worksBusiness, Management…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 10.6×. Every wedge is a field page.

Which keywords describe research at ToolGen (South Korea)?

By fractional works in all years, weighted toward what it does more of than the world: Genome Engineering, RNA-Guided, Gene Therapy, Genomic Integration, Gene Expression, Embryonic Stem Cells, Immunotherapy and Cancer Immunotherapy.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Genome Engineering10▲ 255×1 topic
  2. RNA-Guided10▲ 255×1 topic
  3. Gene Therapy6▲ 31×5 topics
  4. Genomic Integration5▲ 66×2 topics
  5. Gene Expression4▲ 11×13 topics
  6. Embryonic Stem Cells4▲ 81×2 topics
  7. Immunotherapy4▲ 8.6×6 topics
  8. Cancer Immunotherapy4▲ 39×3 topics
  9. Pluripotent Stem Cells3▲ 74×2 topics
  10. Cancer3▲ 3.6×16 topics
  11. AAV3▲ 75×1 topic
  12. Viral Vectors3▲ 75×1 topic
  13. Transcriptional Regulation3▲ 19×6 topics
  14. Tumor Regression3▲ 54×2 topics
  15. Differentiation3▲ 60×2 topics
  16. CAR T Cells3▲ 93×1 topic
  17. Chimeric Antigen Receptor3▲ 93×1 topic
  18. Induced Pluripotent Stem Cells3▲ 113×1 topic
  19. Reprogramming3▲ 113×1 topic
  20. Ribosome3▲ 39×1 topic
  21. Translation3▲ 19×1 topic
  22. Gene Regulation2▲ 22×3 topics
  23. Mitochondrial Dysfunction2▲ 9.1×6 topics
  24. DNA nanotechnology2▲ 30×1 topic
  25. Self-Assembly2▲ 7.9×1 topic
  26. Biopharmaceutical Production2▲ 38×2 topics
  27. Gene Silencing2▲ 24×2 topics
  28. Chromatin2▲ 29×2 topics
  29. Transcription Factors2▲ 19×3 topics
  30. Parkinson's Disease2▲ 11×4 topics
  31. RNA Interference2▲ 21×2 topics
  32. Non-viral Vectors2▲ 31×1 topic
  33. siRNA Delivery2▲ 31×1 topic
  34. Epigenetic Regulation1▲ 9.6×6 topics
  35. Genetic Modification1▲ 52×1 topic
  36. Histone Modifications1▲ 53×1 topic
  37. Immunity1▲ 6.2×2 topics
  38. Transcription1▲ 53×1 topic
  39. Transgenic Animals1▲ 52×1 topic
  40. Tumor Microenvironment1▲ 6.0×5 topics

Which research topics does ToolGen (South Korea) publish most on?

By volume in 2022–2025: CRISPR and Genetic Engineering, Virus-based gene therapy research, CAR-T cell therapy research and Pluripotent Stem Cells Research.

CRISPR and Genetic Engin…3CRISPR and Genetic Engineering: 3 fractional worksVirus-based gene therapy…1Virus-based gene therapy research: 1 fractional worksCAR-T cell therapy resea…1CAR-T cell therapy research: 1 fractional worksPluripotent Stem Cells R…1Pluripotent Stem Cells Research: 1 fractional worksRNA and protein synthesi…0RNA and protein synthesis mechanisms: 0 fractional worksRenal and related cancers0Renal and related cancers: 0 fractional worksRNA Interference and Gene Delivery: 0 fractional worksViral Infectious Diseases and Gene Expression in Insects: 0 fractional worksBRCA gene mutations in cancer: 0 fractional worksAdvanced Glycation End Products research: 0 fractional works
Molecular BiologyGeneticsOncologyClinical Biochemistry

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CRISPR and Genetic Engineering Molecular Biology 3 works
  2. 2 Virus-based gene therapy research Genetics 1 works
  3. 3 CAR-T cell therapy research Oncology 1 works
  4. 4 Pluripotent Stem Cells Research Molecular Biology 1 works
  5. 5 RNA and protein synthesis mechanisms Molecular Biology 0 works
  6. 6 Renal and related cancers Molecular Biology 0 works
  7. 7 RNA Interference and Gene Delivery Molecular Biology 0 works
  8. 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
  9. 9 BRCA gene mutations in cancer Genetics 0 works
  10. 10 Advanced Glycation End Products research Clinical Biochemistry 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available66.7%not open33.3%

World: 28% of research is openly available.

with international co-authors23.6%domestic only76.4%

World: 19% is written across borders.

How has ToolGen (South Korea)'s research output changed?

Output in 2018–2022 was 62% higher than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Seoul

All research institutions in Seoul

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.